Detalles de la búsqueda
1.
Therapeutic potential of the novel Bcl-2/Bcl-XL dual inhibitor, APG1252, alone or in combination against non-small cell lung cancer.
Mol Carcinog;
61(11): 1031-1042, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36066010
2.
The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition.
Pharmacol Res;
175: 105998, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34826601
3.
Proteomic characterization of paired non-malignant and malignant African-American prostate epithelial cell lines distinguishes them by structural proteins.
BMC Cancer;
17(1): 480, 2017 Jul 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28697756
4.
DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models.
J Clin Invest;
134(10)2024 Mar 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38451729
5.
Macrophage-Conditioned Media Promotes Adipocyte Cancer Association, Which in Turn Stimulates Breast Cancer Proliferation and Migration.
Biomolecules;
12(12)2022 11 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-36551185
6.
Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1.
Cancer Gene Ther;
29(11): 1558-1569, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35449204
7.
The novel BET degrader, QCA570, is highly active against the growth of human NSCLC cells and synergizes with osimertinib in suppressing osimertinib-resistant EGFR-mutant NSCLC cells.
Am J Cancer Res;
12(2): 779-792, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35261801
8.
Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation, or both.
Oncogene;
41(12): 1691-1700, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35102249
9.
Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling.
Lung Cancer (Auckl);
12: 1-10, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33574724
10.
MET inhibition downregulates DR4 expression in MET-amplified lung cancer cells with acquired resistance to EGFR inhibitors through suppressing AP-1-mediated transcription.
Neoplasia;
23(8): 766-774, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34233230
11.
Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors.
Mol Cancer Res;
19(10): 1622-1634, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34183449
12.
Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1.
Cancer Gene Ther;
29(11): 1801-1802, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35538225
13.
Elevated Resistin Gene Expression in African American Estrogen and Progesterone Receptor Negative Breast Cancer.
PLoS One;
11(6): e0157741, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27314854
14.
Does the natural product, honokiol, have value in the battle against osimertinib resistance?
Oncoscience;
7(9-10): 73-75, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-33195738
Resultados
1 -
14
de 14
1
Próxima >
>>